Pfizer backs a small Swiss upstart's attempt to discover a non-viral gene therapy
Joël de Beer made it just a few months into his PhD program at ETH Zurich before he dropped out to join the hunt for the holy grail of gene therapy — a non-viral delivery mechanism.
Now that he’s raised $61 million from some big-name backers — including Pfizer’s venture arm — to aid that quest, the pressure is on.
Anjarium Biosciences uncloaked Thursday morning after four years in stealth mode, sporting a Series A round co-led by Abingworth and Gimv. The team of five has set up shop in a picturesque village about 40 minutes outside of Zurich to solve the current challenges of AAV using DNA-based gene vectors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.